Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIDO-361 in Spinal and Bulbar Muscular Atrophy (SBMA)
NCT06411912Phase 2Completed
- Sponsor
- Nido Biosciences
- Start
- Mar 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of nido-361 in spinal and bulbar muscular atrophy (SBMA), sponsored by Nido Biosciences. Primary endpoints: Lean Muscle Volume at 360 days, Adverse Events at 1 year and 2 more. Started Mar 2024; status: completed.
02
Drugs
nido-361
03
Conditions
spinal and bulbar muscular atrophy (SBMA)
Beyond the preview
Go deeper on NCT06411912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06411912.